Source:http://linkedlifedata.com/resource/pubmed/id/18364435
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2008-6-2
|
pubmed:abstractText |
Maturation of dendritic cells (DC) to enhance their capacity to activate T cell immunity to HIV-1 is a key step in immunotherapy of HIV-1 infection with DC. We compared maturation of DC derived from HIV-1-uninfected subjects and infected subjects on antiretroviral therapy (ART) or ART naïve by CD40 ligand (CD40L) and combinations of TLR3 ligand polyinosinic:polycytidylic acid [poly(I:C)] and inflammatory cytokines IFN-gamma, IFN-alpha, IL-1beta, and TNF-alpha. The greatest levels of virus-specific IFN-gamma production by CD8(+) T cells were stimulated by DC treated with CD40L, followed by DC treated with the poly(I:C)-cytokine combination. The highest levels of IL-12p70 were produced by DC treated with CD40L + IFN-gamma, followed by CD40L and the poly(I:C)-cytokine combination. Neutralization of IL-12p70 indicated that it was only partially involved in direct enhancement of antiviral CD8(+) T cell activity. DC stimulation of antiviral CD8(+) T cell reactivity was enhanced by activated CD4(+) T cells at low concentrations but was suppressed at higher CD4(+) T cell concentrations. Maturation of DC with CD40L obviated the need for CD4(+) T cell help and overcame this suppressive activity. Finally, we showed that DC from HIV-1-infected subjects on ART, which were treated with the poly(I:C)-cytokine combination, retained the capacity to produce IL-12p70 and activate anti-HIV-1 CD8(+) T cell responses after restimulation with CD40L, with or without IFN-gamma. Thus, DC from HIV-1-infected subjects can be engineered with CD40L or a poly(I:C)-cytokine combination for enhancing CD8(+) T cell responses to HIV-1, which has potential applications in HIV-1 immunotherapy.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CD40 Ligand,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-12,
http://linkedlifedata.com/resource/pubmed/chemical/TLR3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Toll-Like Receptor 3
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0741-5400
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
83
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1530-40
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:18364435-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:18364435-CD40 Ligand,
pubmed-meshheading:18364435-CD8-Positive T-Lymphocytes,
pubmed-meshheading:18364435-Dendritic Cells,
pubmed-meshheading:18364435-HIV-1,
pubmed-meshheading:18364435-Humans,
pubmed-meshheading:18364435-Interferon-gamma,
pubmed-meshheading:18364435-Interleukin-12,
pubmed-meshheading:18364435-Lymphocyte Activation,
pubmed-meshheading:18364435-Toll-Like Receptor 3
|
pubmed:year |
2008
|
pubmed:articleTitle |
Maturation of dendritic cells for enhanced activation of anti-HIV-1 CD8(+) T cell immunity.
|
pubmed:affiliation |
Graduate School of Public Health and School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|